More of the same with winners drifting higher in the sector and losers drifting lower. I had hoped that volume and interest would have picked up this week but it.
Volume continues to be anemic but perhaps it will start to pick up into a series of conferences (world lung and SITC) and earnings. I say perhaps but it would.
I was in my office yesterday to write but there is really nothing happening in the sector that is exceptionally newsworthy. I was hoping we would have some news today.
We got some news to talk about today and it just so happens to be some good news and some bad news. In both cases, the news is specific enough.
The sector is off to a good start but it is a relatively slow news day but the news was certainly good. It will be interesting to see how the.
We finally got the AXON news and it was pretty decisive. The question now is the impact that it will have on the broader sector. The hope is that enough.
Sarepta Therapeutics, Inc. (SRPT) Nasdaq A quick look at Sarepta’s yearly chart, from the spike to $63.73 after Exondys-51 FDA approval and the drop to $26.66 lowest point by Dec.
We are starting to get some meaningful data this week and while I suspect it will have some broader upside today, I will be curious to see if the sector.
Already a year has passed since Sarepta’s first drug Exondys51 was granted FDA approval on 09/19/2016. The landmark decision by Janet Woodcock, despite the review team’s opposition, gave hope to.
I have been looking around for real meaningful news this morning and there does not seem to be anything compelling. As such, I expect a trend day with the sector.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
It still looks to me that the sector is acting less like a sector and more like an aggregation of individual stocks. That is always true (it is not a.
It is a strong start to the week (broader market) with the sector trudging along higher. There are some very strong moves under the surface but those are both higher.
The sector has been doing well but it seems to have been a bifurcated market with big winners and losers. The broader market seems to be listless which is not.
A relatively quiet start to the week (at least for the sector). North Korea remains a concern but despite the nuclear test the response of the US and South Korea.
The good news and move for the sector continues. In isolation the move higher seems a stretch in terms of the fundamental news that we have seen the past week..
The long sector nightmare is over and we have a merger Monday and GILD did a deal. There was also some interesting BIIB data that has been loss in the.
The sector had a good day yesterday with an early retracement this morning. I am a little surprised that there is not more weakness in the broader market. Last night.